Abstract
TNF-α neutralising agents such as Infliximab (Remicade®), Etanercept (Enbrel®) and the IL-1 receptor antagonist Anakinra (Kineret®), are currently used clinically for the treatment of many inflammatory diseases such as Crohns disease, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis and psoriasis. These protein preparations are expensive to manufacture and administer, need to be injected and can cause allergic reactions. An alternative approach to lowering the levels of TNF-α and IL- 1β in inflammatory disease, is to inhibit the enzymes that generate these cytokines using cheaper small molecules. This paper is a broad overview of the progress that has been achieved so far, with respect to small molecule inhibitor design and pharmacological studies (in animals and humans), for the metalloprotease Tumour Necrosis Factor-α Converting Enzyme (TACE) and the cysteine protease Caspase-1 (Interleukin-1β Converting Enzyme, ICE). Inhibitors of these two enzymes are currently considered to be good therapeutic targets that have the potential to provide relatively inexpensive and orally bioavailable anti-inflammatory agents in the future.
Current Medicinal Chemistry
Title: Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs
Volume: 12 Issue: 25
Author(s): Giang T. Le and Giovanni Abbenante
Affiliation:
Keywords: protease, tace, caspase-1, ice, inhibitor, review
Abstract: TNF-α neutralising agents such as Infliximab (Remicade®), Etanercept (Enbrel®) and the IL-1 receptor antagonist Anakinra (Kineret®), are currently used clinically for the treatment of many inflammatory diseases such as Crohns disease, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis and psoriasis. These protein preparations are expensive to manufacture and administer, need to be injected and can cause allergic reactions. An alternative approach to lowering the levels of TNF-α and IL- 1β in inflammatory disease, is to inhibit the enzymes that generate these cytokines using cheaper small molecules. This paper is a broad overview of the progress that has been achieved so far, with respect to small molecule inhibitor design and pharmacological studies (in animals and humans), for the metalloprotease Tumour Necrosis Factor-α Converting Enzyme (TACE) and the cysteine protease Caspase-1 (Interleukin-1β Converting Enzyme, ICE). Inhibitors of these two enzymes are currently considered to be good therapeutic targets that have the potential to provide relatively inexpensive and orally bioavailable anti-inflammatory agents in the future.
Export Options
About this article
Cite this article as:
Le T. Giang and Abbenante Giovanni, Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462851
DOI https://dx.doi.org/10.2174/092986705774462851 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Wealth of Opportunity - The C1 Domain as a Target for Drug Development
Current Drug Targets Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis
Current Drug Targets Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Three Dimensional Molecular Field Analysis of Thiomorpholine Analogs of TACE Inhibitors Using Receptor Based Alignment
Letters in Drug Design & Discovery The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry The Dramatic Role of IFN Family in Aberrant Inflammatory Osteolysis
Current Gene Therapy Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Proteome/Protein/Peptide in Molecular Medicine (Guest Editor: John M. Luk)
Protein & Peptide Letters Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Rheumatology: A Force for Change in Monoclonal Antibodies
Current Pharmaceutical Design